Menu Search
Equities

XORTX Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
ANUA:STU

XORTX Therapeutics Inc

Actions
  • Price (EUR)0.341
  • Today's Change-0.053 / -13.45%
  • Shares traded66.00
  • 1 Year change-60.26%
  • Beta0.1425
Data delayed at least 15 minutes, as of Feb 05 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-2.66m
  • Incorporated2011
  • Employees3.00
  • Location
    XORTX Therapeutics Inc3710 - 33rd Street NWCALGARY T2L 2M1CanadaCAN
  • Phone+1 (403) 455-7727
  • Fax+1 (403) 607-2621
  • Websitehttps://www.xortx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.